{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-129170","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.279264+00:00","generated_at":"2026-05-15T08:40:37.907559+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Kymera Therapeutics amends bylaws to designate federal courts for securities claims","bullets":["Board approved amendment to Second Amended and Restated Bylaws on March 25, 2026.","Federal district courts designated exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934.","Amendment effective immediately; company may consent to alternative forum in writing.","Change made in response to recent amendments to Delaware General Corporation Law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-129170","json":"https://secwatch.observer/filing/0001193125-26-129170.json","markdown":"https://secwatch.observer/filing/0001193125-26-129170.md","text":"https://secwatch.observer/filing/0001193125-26-129170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/d122194d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:40:37.907559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6754406f86add6aa7f6bad4c28e28c66c7c2a2b6","claim":"Kymera Therapeutics, Inc.: Amended bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-25).","evidence_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001682852-26-000101","ticker":"MRNA","company_name":"Moderna, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000101","json":"https://secwatch.observer/filing/0001682852-26-000101.json","markdown":"https://secwatch.observer/filing/0001682852-26-000101.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/mrna-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm"}},{"accession":"0000023217-26-000015","ticker":"CAG","company_name":"CONAGRA BRANDS INC.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Conagra brands board approves amended bylaws allowing virtual shareholder meetings","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000023217-26-000015","json":"https://secwatch.observer/filing/0000023217-26-000015.json","markdown":"https://secwatch.observer/filing/0000023217-26-000015.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/23217/000002321726000015/0000023217-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/23217/000002321726000015/tmb-20260505x8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"On May 5, 2026, the Board of Directors of Conagra Brands, Inc. (the “Company”) approved Amended and Restated Bylaws of Conagra Brands, Inc. (“Amended and Restated Bylaws”), effective on such date.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/23217/000002321726000015/0000023217-26-000015-index.htm"}},{"accession":"0001193125-26-201434","ticker":"AVLN","company_name":"Avalyn Pharma Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Avalyn Pharma adopts amended charter and bylaws upon IPO consummation","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-201434","json":"https://secwatch.observer/filing/0001193125-26-201434.json","markdown":"https://secwatch.observer/filing/0001193125-26-201434.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526201434/0001193125-26-201434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526201434/ck0001540171-20260501.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders to become effective immediately upon effectiveness of the Registration Statement, became effective.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526201434/0001193125-26-201434-index.htm"}},{"accession":"0001437749-26-014317","ticker":"PLOW","company_name":"DOUGLAS DYNAMICS, INC","filed_at":"2026-05-01T23:59:59+00:00","headline":"Douglas Dynamics shareholders approve officer exculpation amendment, elect directors","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-014317","json":"https://secwatch.observer/filing/0001437749-26-014317.json","markdown":"https://secwatch.observer/filing/0001437749-26-014317.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287213/000143774926014317/0001437749-26-014317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287213/000143774926014317/plow20260430_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"On April 30, 2026, Douglas Dynamics, Inc. (the “Company”) amended the Company’s Fourth Amended and Restated Certificate of Incorporation to provide for exculpation from personal liability for certain officers as permitted by Delaware law (the “Amendment”) by filing a Certificate of Amendment with the Secretary of State of Delaware.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1287213/000143774926014317/0001437749-26-014317-index.htm"}},{"accession":"0001104659-26-052878","ticker":"CGEH","company_name":"Capstone Energy Plus, Inc.","filed_at":"2026-04-30T23:59:59+00:00","headline":"Capstone Green Energy Holdings changes name to Capstone Energy+, effective April 30, 2026; ticker CGEH unchanged.","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.1,"calibrated_materiality_score":0.1,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-052878","json":"https://secwatch.observer/filing/0001104659-26-052878.json","markdown":"https://secwatch.observer/filing/0001104659-26-052878.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1009759/000110465926052878/0001104659-26-052878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1009759/000110465926052878/cgeh-20260429x8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"In connection with the Name Change, the Company’s Board of Directors also approved amended and restated bylaws, effective as of April 30, 2026, to reflect the Name Change (the “Amended and Restated Bylaws”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1009759/000110465926052878/0001104659-26-052878-index.htm"}},{"accession":"0001193125-26-197435","ticker":null,"company_name":"Phillip Street BDC LLC","filed_at":"2026-04-30T23:59:59+00:00","headline":"Phillip Street BDC LLC renamed from Phillip Street Middle Market Lending Fund LLC effective April 24, 2026","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-197435","json":"https://secwatch.observer/filing/0001193125-26-197435.json","markdown":"https://secwatch.observer/filing/0001193125-26-197435.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1948368/000119312526197435/0001193125-26-197435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1948368/000119312526197435/d148011d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"Effective April 24, 2026, Phillip Street BDC LLC (the “ Company ”) changed its name from “Phillip Street Middle Market Lending Fund LLC” to “Phillip Street BDC LLC” by filing a certificate of amendment to its Certificate of Formation (the “ Certificate of Formation Amendment ”) with the Secretary of State of the State of Delaware.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1948368/000119312526197435/0001193125-26-197435-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001628280-26-039465","ticker":"IOT","company_name":"Samsara Inc.","filed_at":"2026-06-01T20:07:41+00:00","headline":"Samsara Inc. reincorporates from Delaware to Nevada, effective June 1, 2026","event_type":"other_material","sec_items":["3.03","5.03","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039465","json":"https://secwatch.observer/filing/0001628280-26-039465.json","markdown":"https://secwatch.observer/filing/0001628280-26-039465.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/0001628280-26-039465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/iot-20260601.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm","comparable_excerpt":"the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) became effective on June 1, 2026, at 12:02 a.m. Pacific Time","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/0001628280-26-039465-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}